Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck (NYSE:MRK) announced Wednesday that a Phase 3 trial designed to test its anti-PD-1 therapy Keytruda (pembrolizumab) as ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

Keytruda cuts risk of death by 20% in certain patients with gastric or gastroesophageal junction as a first-line combination ...

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

Merck (MRK) announced the Japanese Ministry of Health, Labor and Welfare has approved new indications for KEYTRUDA or pembrolizumab, ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Keytruda shows promise as a first line option in cervical cancer cutting patients' mortality risk by a third in a Phase 3 ...